ANIP - Company ID 0001023024
The table below shows ANI PHARMACEUTICALS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $883.37M | $614.38M | $486.82M | $316.38M | $216.14M | $208.47M |
| Cost of revenue | - | - | - | - | - | $87.16M |
| Gross profit | - | - | - | - | - | - |
| R&D | $51.66M | $44.58M | $34.29M | $22.32M | $11.37M | $16.00M |
| SG&A |
ANI PHARMACEUTICALS INC reported annual revenue of $883.37M for fiscal year 2025. That is up 43.8% from $614.38M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $128.62M (FY 2016) to $883.37M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $317.75M |
| $249.64M |
| $161.70M |
| $124.04M |
| $84.29M |
| $64.99M |
| Operating income | $111.09M | $584.00K | $46.97M | -$35.28M | -$39.79M | -$16.02M |
| Income tax | $17.45M | -$3.69M | $1.09M | -$14.77M | -$13.46M | -$3.41M |
| Net income | $78.00M | -$19.00M | $19.00M | -$48.00M | -$43.00M | -$22.55M |
| EPS (diluted) | $3.32 | -$1.04 | $0.85 | -$3.05 | -$3.40 | -$1.88 |